Skip to content

MIND-Matosinhos: Multiple Interventions to Prevent Cognitive Decline

Multiple Interventions to Prevent Cognitive Decline (MIND-Matosinhos) - a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05383443
Enrollment
300
Registered
2022-05-20
Start date
2020-12-15
Completion date
2022-12-31
Last updated
2022-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognition Disorder, Cognitive Dysfunction, Cognitive Impairment, Memory Disorders, Neurocognitive Disorders

Keywords

Aging, Cognitive Dysfunction, Cognition Disorders, Dementia, Diet, Healthy, Exercise Therapy, Hearing Loss, Memory Disorders, Multidomain intervention, Randomized Controlled Trial

Brief summary

The present study aims to quantify the impact of a multidomain approach to prevent cognitive decline in individuals from the general population at-high risk of dementia. It will be based on five distinct components: 1) cognitive training; 2) physical exercise; 3) nutrition education; 4) capacitation to deal with cognitive decline; 5) assessment and correction of hearing loss.

Detailed description

This is a community-based randomized controlled trial (RCT), which will be implemented in Matosinhos municipality (Portugal) and will be conducted over three months, possibly extensible up to 12 months. Eligible individuals (n=300) will be randomized (1:1) into two arms: intervention and control groups. The intervention plan will be composed by five non-pharmacological strategies, namely: 1) cognitive training; 2) physical exercise; 3) nutrition education; 4) capacitation to deal with cognitive decline; 5) assessment and correction of hearing loss. This plan will be applied to both groups, but with lower intensity among the control group. Participants' characteristics will be assessed at baseline and at three months; for those who complete one year of intervention, additional follow-ups at six and 12 months after the beginning of the intervention will be conducted. These evaluations will cover the following domains: sociodemographic, lifestyle, health and anthropometric characteristics; cognitive function; subjective memory complains; symptoms of anxiety and depression; quality of life; physical performance; levels of glycated hemoglobin and 24-hour urinary sodium, potassium, creatinine excretion as well as pH. The results of the present study may guide future clinical practices and health policies aiming to prevent cognitive decline and reduce the overall burden of dementia.

Interventions

BEHAVIORALCognitive training

This component will comprise the following activities: i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously).

BEHAVIORALPhysical exercise

This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher: i. In-person group training (monthly); ii. In-person group training or remote synchronous training (group) or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic.

BEHAVIORALNutrition education

This component will be based on the following activities: i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly).

BEHAVIORALCapacitation to deal with cognitive decline

This component will be based on in-person 60-minute group sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.

This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.

Sponsors

Instituto de Saude Publica da Universidade do Porto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-85 years; * Score equal or higher than the validated cutoff points defined as 2 standard deviations below the mean for age and education in the Montreal Cognitive Assessment (MoCA); * ≥6 points on the Cardiovascular Risk Factors, Aging and Dementia Dementia Risk Score (CAIDE); * ≥4 years of schooling.

Exclusion criteria

* Medical disability that contraindicates physical activity; * Lack of autonomy in daily activities; * Previous diagnosis of dementia or severe incapacity.

Design outcomes

Primary

MeasureTime frameDescription
Adherence to the Mediterranean dietUp to 12 monthsVariation of participant's self-reported adherence to the Mediterranean diet, assessed using the Mediterranean food pattern scale (MEDAS), between the baseline assessment and the end of follow-up. This scale varies from 0 (lowest adherence to the Mediterranean diet) to 14 points (highest adherence to the Mediterranean diet). A score over 10 points indicates good adherence to the Mediterranean diet.
Self-reported quality of lifeUp to 12 monthsVariation of participant's quality of life, assessed using the EuroQol Group scale - 5 dimensions (EQ-5D) scale, between the baseline assessment and the end of follow-up. This scale is subdivided in two subscales: a) five multiple choice questions, with five response possibilities, which produce a score that varies from 5 (best score) to 25 points (worst score); b) visual analogic scale, that varies from 0 (worst score) to 100 (best score).

Secondary

MeasureTime frameDescription
Cognitive performance 2Up to 12 monthsVariation of participant's cognitive performance assessed using a neuropsychological battery tests, between the baseline assessment and the end of the follow-up. This will be reported in the format of a Z-score, assuming positive and negative values. Higher scores indicate better cognitive performance.
Anxiety and depressionUp to 12 monthsVariation of the anxiety and depression scores, assessed using the Hospital Anxiety and Depression Scale (HADS), between the baseline assessment and the end of the follow-up. This scale varies from 0 (best score) to 21 points (worst score).
Handgrip strengthUp to 12 monthsVariation of participant's handgrip strength, assessed using a dynamometer, between the baseline assessment and the end of the follow-up.
Agility 1Up to 12 monthsVariation of participant's agility and balance, assessed using the Timed Up and Go Test scale, between the baseline assessment and the end of the follow-up. This is measured in time units (seconds) and varies from 0 (best score) to infinite (worst score).
Agility 2Up to 12 monthsVariation of participant's agility and balance, assessed using the Unipedal Stance Test, between the baseline assessment and the end of the follow-up. This is measured in time units (seconds) and varies from 0 (best score) to infinite (worst score).
Upper body strengthUp to 12 monthsVariation of participant's upper body strength assessed using the 30-second arm curl test from the Senior Fitness Test.
Lower body strengthUp to 12 monthsVariation of participant's lower body strength assessed using the 30-second chair stand test from the Senior Fitness Test.
Upper body flexibilityUp to 12 monthsVariation of participant's upper body flexibility assessed using the back-scratch test from the Senior Fitness Test.
Lower body flexibilityUp to 12 monthsVariation of participant's lower body flexibility assessed using the chair sit-and-reach test from the Senior Fitness Test.
Agility 3Up to 12 monthsVariation of participant's agility and dynamic balance assessed using the 8-foot distance test (2,44 meters) from the Senior Fitness Test.
Aerobic enduranceUp to 12 monthsVariation of participant's aerobic endurance assessed using the 2-minute step test from the Senior Fitness Test.
Memory complaintsUp to 12 monthsVariation of the self-reported memory complaints, assessed using the Subjective Memory Complaints Scale, between the baseline assessment and the end of follow-up. This scale varies from 0 (best score) to 21 points (worst score). Scores over three points indicate the presence of self-reported memory complaints.
Levels of glycated hemoglobinUp to 12 monthsVariation of participant's levels of glycated hemoglobin, between the baseline assessment and the end of follow-up. This parameter will be measured through a laboratory analysis of participants' blood sample and will be used to analyze glycemic control.
24-hour urinary sodium excretionUp to 12 monthsVariation of participant's urinary sodium excretion, between the baseline and the follow-up assessments. This parameter will be measured through a laboratory analysis of participants' 24-hour urinary samples and will be analyzed as a proxy of dietary salt intake.
24-hour urinary potassium excretionUp to 12 monthsVariation of participant's urinary potassium excretion, between the baseline and the follow-up assessments. This parameter will be measured through a laboratory analysis of participants' 24-hour urinary samples and will be analyzed as a proxy of dietary potassium intake.
Body mass indexUp to 12 monthsVariation of participant's body mass index between the baseline assessment and the end of follow-up.
Blood pressureUp to 12 monthsVariation of participant's systolic and diastolic blood pressure, between the baseline evaluation and the end of follow-up.
Functional capacity to perform instrumental activities of daily livingUp to 12 monthsVariation of participant's independence on performing instrumental activities of daily living, using the Lawton & Brody scale, which ranges from 0 to 8 and higher scores represent increased functional capacity to perform instrumental activities.
Time of follow-upUp to 12 monthsNumber of days between the first and the last session attended by the participant.
Implemented sessionsUp to 12 monthsProportion of sessions implemented, calculated as the number of sessions that the research team was able to implement divided by the total number of sessions planned.
Complete assessment of participantsUp to 12 monthsFor each study outcome, proportion of participants with complete information, calculated at baseline and different moments of follow-up, as the number of participants with complete information divided by the total number of participants evaluated.
Adherence to each component of the interventionUp to 12 monthsProportion of adherence to each component of the intervention and to different intervention modalities (remote/in person), calculated as the number of sessions attended divided by the total number of sessions implemented. For remote cognitive training the outcome will be the absolute number of sessions.
DropoutUp to 12 monthsProportion of participants who dropped out of the study, calculated as the number of participants who dropped out after attending at least one session divided by the total number of participants who attended at least one session.
Lower limb functionUp to 12 monthsVariation of participant's lower limb function, assessed using the Short Physical Performance Battery (SPPB), which tests 3 dimensions: standing balance, walking speed, and chair stands. Each component is scored between 0-4; total score ranges from 0 (poor performance) to 12 (best performance).
Cognitive performance 1Up to 12 monthsVariation of participant's cognitive performance assessed using the Montreal Cognitive Assessment, between the baseline assessment and the end of the follow-up. This scale varies from 0 (worst cognitive performance) to 30 points (best cognitive performance).

Countries

Portugal

Contacts

Primary ContactAna Rute Costa, PhD
arcosta@ispup.up.pt+351 22 206 1820

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026